Brady Collins
Tuberculous meningitis is a major problem and an important cause of death in some countries. The BCG vaccine has been proven to be effective in reducing the risk of tuberculosis and provides protection against the development of meningeal and miliary tuberculosis in newborns. However, the question of how protective the BCG vaccine is against tuberculous meningitis remains. Several studies have been conducted to determine the efficacy of the BCG vaccine in preventing tuberculous meningitis, with varying results. While some studies suggest that the BCG vaccine provides significant protection against tuberculous meningitis, others indicate that its effectiveness may depend on various factors such as malnutrition, socioeconomic status, and time since vaccination.
| Characteristics | Values |
|---|---|
| Efficacy against TB meningitis | 50% to 87% |
| Efficacy against death from TB | 71% |
| Efficacy against meningeal and miliary TB | 80% |
| Efficacy against TB | 64% |
| Effectiveness in children with malnutrition or low socioeconomic status | Lower |
| Effectiveness in children with underweight | Lower |
| Longevity of efficacy | Up to 10 years |
| Form of vaccine | Injection |
| Number of doses | 1 |
| Type of vaccine | Live vaccine |
| Vaccine safety | Rare mild side effects |
Explore related products
What You'll Learn
- The BCG vaccine is moderately effective in protecting against TB meningitis
- The efficacy of the vaccine is influenced by socioeconomic status, malnutrition, and weight
- The vaccine is only recommended for people at higher risk of TB
- The BCG vaccine is a live vaccine with a weakened form of TB bacteria
- The vaccine is given as an injection into the upper left arm
The BCG vaccine is moderately effective in protecting against TB meningitis
The Bacillus Calmette-Guerin (BCG) vaccine is a live vaccine that contains a weakened form of tuberculosis (TB) bacteria. It is given as an injection into the upper part of the left arm, and only one dose is needed. The BCG vaccine is particularly helpful in protecting babies and young children against more serious forms of TB, such as TB meningitis.
The protective effect of the BCG vaccine against TB meningitis has been the subject of several studies. While some studies suggest that the vaccine offers significant protection against TB meningitis, others indicate that its effectiveness may be moderate or variable. For example, a meta-analysis by Colditz found that the BCG vaccine provided 50% protection against any TB disease, 64% protection against TB meningitis, and 71% protection against death from tuberculosis.
In countries with a high incidence of tuberculosis, such as Bosnia and Herzegovina, the BCG vaccine plays a crucial role in preventing TB meningitis in newborns. A decrease in BCG immunization coverage in these countries has been associated with an increase in tuberculous meningitis cases. For instance, during 2002 in Bosnia and Herzegovina, when BCG vaccination coverage in newborns was 90%, the incidence rate of tuberculous meningitis was 19 per 100,000. However, with a 68% decrease in BCG immunization coverage in 2003, the incidence of tuberculous meningitis rose significantly.
The effectiveness of the BCG vaccine may be influenced by various factors, such as malnutrition, low weight, or low socioeconomic status. Additionally, the duration of protection provided by the vaccine is also important to consider. While some studies suggest that the protection offered by the BCG vaccine may persist for up to 10 years after infant vaccination, others indicate that its effectiveness may wane over time.
In summary, while the BCG vaccine is generally considered to provide moderate protection against TB meningitis, its effectiveness may vary depending on individual factors and the epidemiological context.
Religious Exemption for Vaccines: Illinois' Legal Requirements
You may want to see also
Explore related products
$131.84 $169.99
The efficacy of the vaccine is influenced by socioeconomic status, malnutrition, and weight
The efficacy of the BCG vaccine is influenced by several factors, including socioeconomic status, malnutrition, weight, geography, and genetics.
Socioeconomic status is a critical factor in the effectiveness of the BCG vaccine. Children from low socioeconomic backgrounds have been found to have a reduced protective effect from the vaccine. This could be due to various reasons, including limited access to proper nutrition, healthcare, and sanitary living conditions, all of which can impact the immune system's response to the vaccine.
Malnutrition and weight are also significant factors influencing vaccine efficacy. Malnutrition, particularly undernutrition, can compromise the integrity of cellular immunity, making individuals more susceptible to infections like tuberculosis. Studies have shown that malnourished individuals exhibit bacterial dissemination to the lymph nodes, spleen, and liver after receiving the BCG vaccine. Additionally, low birth weight infants have less mature immune systems compared to normal birth weight infants, which may impact the effectiveness of the vaccine.
The efficacy of the BCG vaccine also varies depending on geographical location. Trials in the UK consistently show a protective effect ranging from 60% to 80%, while trials conducted in other regions have shown no protective effect. The protective effect appears to decrease as one moves closer to the equator. This variation could be due to differences in environmental factors, exposure to other bacterial infections, and conditions in the laboratory where the vaccine is grown.
Genetic variation in both the BCG strains and the populations being vaccinated may also play a role in the variable efficacy of the vaccine. However, this hypothesis is disputed, as the Birmingham BCG trial in 1988 showed a protective effect in children of families from the Indian subcontinent, a region where vaccine efficacy was previously thought to be zero.
It is important to note that while these factors influence the efficacy of the BCG vaccine, it remains the only licensed vaccine against tuberculosis, and it has been shown to provide significant protection against tuberculous meningitis, especially in the pediatric age group.
Vaccines: Anti-Rabies Included in 5-in-1 Shot?
You may want to see also
Explore related products
The vaccine is only recommended for people at higher risk of TB
The Bacille Calmette-Guérin (BCG) vaccine is a preventative measure against TB disease. While anyone can contract tuberculosis, certain groups are at higher risk of developing active TB disease once infected with TB germs. The BCG vaccine is often given to infants and small children in countries where TB is prevalent.
Children, especially those under five, are at a higher risk of developing TB disease once infected with TB germs. This is because their immune systems are weaker. In countries with high and moderate TB incidence, prevention from the most severe complications of tuberculosis can only be achieved with a high coverage of the universal BCG neonatal immunization. For example, in Bosnia and Herzegovina, where TB incidence is high, BCG vaccination is performed immediately after birth to prevent TB meningitis in newborns. A decrease in immunization coverage in 2003 led to an increase in tuberculous meningitis cases.
Other factors that influence the efficacy of the BCG vaccine include malnutrition, being underweight, and low socioeconomic status. The vaccine's effectiveness also wanes over time. A 1995 meta-analysis concluded that BCG efficacy may persist for 10 years after infant vaccination.
In summary, while the BCG vaccine offers protection against tuberculous meningitis, it is only recommended for people at higher risk of TB, such as infants and young children in countries with a high prevalence of TB, as they are more susceptible to infection and severe disease progression.
Vaccination Status for Attending 49ers Games
You may want to see also
Explore related products
$90.63 $116.99
The BCG vaccine is a live vaccine with a weakened form of TB bacteria
The BCG vaccine is a live vaccine, which means it contains a weakened form of the tuberculosis (TB) bacteria. It is given as an injection into the upper part of the left arm, and only one dose is needed. The vaccine is particularly helpful in protecting babies and young children against more serious forms of TB, such as TB meningitis, which is a major cause of death in some countries.
Several studies have found that neonatal BCG vaccination reduces the risk of tuberculosis and provides protection of more than 80% against the development of meningeal and miliary tuberculosis in newborns. A case-control study in São Paulo, Brazil, indicated that the efficacy of BCG was 84.5% for neighbourhood controls and 80.2% for hospital controls. Another study in Bosnia and Herzegovina found that during 2002, when BCG vaccination coverage in newborns was 90%, the incidence rate of tuberculous meningitis was 19 per 100,000. However, when there was a 68% decrease in vaccination coverage in 2003, the incidence of tuberculous meningitis increased.
A meta-analysis by Colditz found that the BCG vaccine has a significant protective effect against tuberculous meningitis, ranging from 75% to 87%. However, the protective effect may decrease over time, with the meta-analysis concluding that efficacy may persist for 10 years after infant vaccination. Other factors that may influence the effectiveness of the BCG vaccine include malnutrition, low weight, and low socioeconomic status.
While the BCG vaccine is generally safe, it is not suitable for everyone. It is not recommended for individuals with a weakened immune system, such as those with a family history of HIV or severe combined immunodeficiency (SCID). Additionally, those with a high temperature or skin infection should wait until they have recovered before receiving the vaccine.
Vaccines: Immune System Superpowers Explained
You may want to see also
Explore related products
The vaccine is given as an injection into the upper left arm
The BCG vaccine is recommended for people at higher risk of contracting tuberculosis (TB). This includes babies and children, travellers, and people whose work puts them at risk. The vaccine is particularly helpful in protecting babies and young children against more serious forms of TB, such as TB meningitis.
The BCG vaccine is given as a single injection into the upper left arm. Specifically, it is injected into the insertion of the deltoid muscle in the arm. This site is used because it has the smallest local complication rate. The buttock can also be used as an alternative site of administration as it provides better cosmetic outcomes.
The BCG vaccine is usually given to babies when they are around 28 days old. It is important to note that babies who may have a weakened immune system, for example due to a family history of HIV or severe combined immunodeficiency (SCID), should not receive the vaccine.
Before administering the BCG vaccine, a tuberculin skin test is often carried out to see if the individual already has TB or has had it before. This involves injecting a small amount of liquid under the skin. If the skin reacts, it indicates the presence of TB, and the individual should not receive the BCG vaccine.
Overall, the BCG vaccine is considered safe and effective in providing protection against TB meningitis, with studies showing a 75-87% protective effect.
Pregnant Women: Vaccines and Testing
You may want to see also
Frequently asked questions
Yes, the BCG vaccine provides protection against tuberculous meningitis. It is particularly helpful in protecting babies and young children against more serious forms of TB, such as TB meningitis.
The BCG vaccine has been proven to be effective in reducing the risk of tuberculous meningitis. Studies have shown that it provides protection higher than 80% against the development of meningeal and miliary tuberculosis in newborns. A case-control study in São Paulo, Brazil, indicated that the efficacy of BCG was 84.5% for neighbourhood controls and 80.2% for hospital controls. Another recent meta-analysis proved its protective efficacy as 64% against tuberculosis meningitis.
The effectiveness of the BCG vaccine may be influenced by various factors such as malnutrition, low weight, or low socioeconomic status. It has also been suggested that the efficacy of the BCG vaccine may decrease over time, with one meta-analysis concluding that its efficacy may persist for up to 10 years after infant vaccination.
The BCG vaccine is generally safe for newborns, but it is not suitable for everyone. It is a live vaccine, which means it contains a weakened form of the tuberculosis (TB) bacteria. It should not be given to babies with a weakened immune system, for example, due to a family history of HIV or severe combined immunodeficiency (SCID). Additionally, those with a high temperature or skin infection should wait until they have recovered before receiving the vaccine.
